What does this research mean for the field?

Growth hormone therapy can induce stridor due to glottic or subglottic edema in patients with Prader–Willi Syndrome. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

This research aims to examine the effects of growth hormone therapy on airway changes in Prader-Willi Syndrome patients.

March 14, 2026Clinical Case Reports0 citationsOpen Access

View Full Paper

Growth Hormone‐Induced Stridor in a Patient With Prader–Willi Syndrome

ASAnthony SaadRutgers, The State University of New Jersey HZH. ZakiRutgers, The State University of New Jersey AMAdarsh Menon

Key Points

This research aims to examine the effects of growth hormone therapy on airway changes in Prader-Willi Syndrome patients.
Analyzed cases of Prader-Willi Syndrome patients undergoing growth hormone therapy.
Assessed airway complications such as stridor and edema.
Reviewed patient medical histories for complex airway issues.
Growth hormone therapy is linked to cases of glottic and subglottic edema.
Some patients experience stridor despite lacking adenotonsillar tissue.
Clinicians should be vigilant about medication-induced airway changes.

Abstract

ABSTRACT While growth hormone therapy has been associated with the potential risk of upper airway obstruction and hypertrophy, it may also cause glottic or subglottic edema and stridor, even in patients without adenotonsillar tissue. Clinicians should consider medication‐induced airway changes in Prader–Willi Syndrome patients with complex airway histories to optimize management.

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Growth Hormone‐Induced Stridor in a Patient With Prader–Willi Syndrome

Key Points

Abstract

Cite This Study

Also Consider

Also Consider